ALSO NOTED: Neurochem pursues new Kiacta trial; Teva drug fails ALS trial; Columbus tapped as promising new life sciences hub;

> Neurochem is forging ahead with plans to launch a new late-stage trial for Kiacta in a renewed bid for regulatory approval. Regulators had declined to approve the amyloidosis therapy, saying they needed to see more data. Release

> Teva says that a mid-stage trial of glatiramer acetate (GA) 40 mg for ALS failed primary and secondary endpoints. Release

> In a review of up-and-coming tech hubs, Forbes picked Columbus, OH as the most promising new hub on the U.S. map, in part because of the life sciences work being done at the Battelle Memorial Institute. Palm Beach County also lands high up on the list, as new R&D institutes spring up for discovery work. Report

> CyDex has filed for an IPO that could be valued at up to $50 million. The Lenexa, KS-based developer has patented technology used to improve solubility, stability, bioavailability, safety and dosing. Release

> Dani Bolognesi, the co-founder of Trimeris, is back at the helm of a start-up biotech company, hoping that B3Bio can score advances for inflammation, cancer and infection. The start-up is relying on technology developed at Duke and the University of Texas. Story

> Sciele Pharma has paid $29 million to buy Verus's Twinject epinephrine auto-injector along with other products. Release

> Juvaris BioTherapeutics has tapped Grant Pickering to replace founder Martin Cleary at the helm. Pickering had earlier founded Pharmada, a developer of cancer therapies. Cleary remains as chairman of the board. Release

> Avexa announced "excellent" data from a Phase IIb trial of its HIV therapy, with 90 percent of patients achieving undetectable viral loads after 48 weeks of therapy. Report

> Urigen announced positive mid-stage results for its experimental therapy for a painful bladder syndrome. Release

> The investment firm Warburg Pincus has taken a 13.7 percent stake in ZymoGenetics. Report

> Researchers figured out how two different cancer drugs--Avastin and Erbitux--might lead to side effects. Report

> Yesterday, the embattled Endo Pharmaceuticals named a pharma veteran David Holveck (photo), who some call "Mr. Fix-It," to replace its departed executive officer. Report

And Finally… Hong Kong closed its schools after three children died from influenza. Officials say there's no sign of SARS or bird flu in the outbreak. Article

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.